Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris

Table 2

Age, cutaneous involvement, and treatment used by Pemphigus vulgaris patients.

	Gender	Age (years)	Cutaneous involvement	Treatment period	Concomitant medications (dosage)
(1)	Female	43	No lesions	4 years	Prednisone (5 mg), dapsone (100 mg)
(2)	Male	64	Mild hyperpigmentation	9 years	Dapsone (50 mg)
(3)	Female	21	99% hyperpigmentation	3 years	Prednisone (10 mg), dapsone (100 mg), vitamin D
(4)	Female	38	99% hyperpigmentation	3 years	Prednisone (15 mg), dapsone (150 mg), vitamin D
(5)	Female	68	37% erythema	1 year	Prednisone (20 mg)
(6)	Female	53	9% hyperpigmentation	1 year	Predisim (3 mg), azathioprine
(7)	Female	48	No lesions	1 year	Prednisone (30 mg), Dapsone (100 mg)
(8)	Female	35	No lesions	5 years	Prednisone (20 mg), dapsone (80 mg)
(9)	Female	12	99% hyperpigmentation	4 months	Prednisone (20 mg)
(10)	Female	47	90% hyperpigmentation and erythema	6 years	Prednisone (20 mg)
(11)	Male	16	36% hyperpigmentation	3 years	Prednisone (20 mg)
(12)	Male	26	Lesions in granulation phase	2 years	Cyclosporine (250 mg)
(13)	Female	48	40% granulomatous lesions	3 years	Prednisone (20 mg), dapsone (100 mg)
(14)	Male	63	Oral lesions and bruises on segments	6 months	Prednisone (60 mg)
(15)	Male	28	90% active lesions and erythema	1 year	Prednisone (60 mg), dapsone (100 mg)
(16)	Female	46	99% acute lesions	3 months	Prednisone (60 mg), dapsone (100 mg)
(17)	Female	ni	99% acute lesions	11 months	Prednisone (60 mg)
(18)	Female	47	99% acute lesions and hyperpigmentation	2 years
(19)	Female	50	54% hyperpigmentation and erythema	2 years	Prednisone (50 mg), Dapsone (100 mg), levothyroxine
(20)	Female	35	36% granulomatous lesions		Prednisone (40 mg), dapsone (100 mg)